KZIA 6-K SEC Filing Analysis

Latest settled — T+5d

KZIA ▲ +0.40% at T+5d

LONG call ✓ call won +0.40% · α vs SPY -0.68% · entry $12.51 → $12.56

Next anchor: T+20d in 11d

Currently $14.28 · +14.15% from $12.51 entry

Entry anchored
May 22, 03:45 PM ET
via Databento tick

T+1d

-2.80%

call -2.80% · α -2.81%

$12.16

settled 17d ago

T+5d

+0.40%

call +0.40% · α -0.68%

$12.56

settled 11d ago

T+20d

—

call — · α —

—

in 11d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Kazia Therapeutics announced expansion of its Phase 1b trial of paxalisib in advanced TNBC from 12 to 36 patients following encouraging safety and tolerability data. The company also stated it withdrew ASCO abstracts to protect intellectual property. This is a positive clinical update for an early-stage asset in an underserved indication, but no efficacy data were disclosed and the trial remains small.

Actionable Insight

The trial expansion signals growing confidence in paxalisib's safety profile, but investors should await formal efficacy data (ORR/PFS) before assigning material value. Withdrawal of ASCO abstracts suggests potential IP progress, which could be a positive catalyst if filings materialize. Monitor for next clinical update or patent announcement.

Key Facts

Phase 1b trial enrollment expanded from 12 to 36 patients in paxalisib plus pembrolizumab and chemotherapy for advanced TNBC
Expansion based on continued encouraging safety, tolerability, and clinical activity data
ASCO 2026 abstracts withdrawn to protect intellectual property; withdrawal not related to safety concerns
Additional clinical and translational updates expected in coming months (2026-2027)

Financial Impact

No financial figures disclosed; clinical expansion at early stage with no revenue impact yet

Risk Factors

Early-stage data may not replicate in larger or later-stage trials
Withdrawal of ASCO abstracts raises questions about IP strategy; could signal competitive pressure
No new financial or partnership news; funding for expanded trial not specified

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001213900-26-060779
Document: ea0292123-6k_kazia.htm	0001213900-26-060779
Document: 0001213900-26-060779-index-headers.html	0001213900-26-060779
Document: 0001213900-26-060779-index.html	0001213900-26-060779
Document: 0001213900-26-060779.txt	0001213900-26-060779

7 reports for KZIA

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +49.05%Apr 13, 2026

Filters

Reports for KZIA — sortable, filterable
	Type				Now
Jun 2, 2026 11d ago	6-K NEUTRAL ★ 3/10	$11.79 $10.95	▼ −7.12%	▼ −6.43%	$14.28 (+21.12%)
May 26, 2026 18d ago	6-K BULLISH ★ 5/10	$12.51 $12.16	▼ −2.80%	▼ −2.81%	$14.28 (+14.15%)
Apr 27, 2026 6w ago	6-K BULLISH ★ 7/10	$11.95 $11.85	▼ −0.84%	▼ −0.35%	$14.28 (+19.50%)
Apr 15, 2026 8w ago	6-K BULLISH ★ 7/10	$10.00 $10.92	▲ +9.20%	▲ +8.95%	$14.28 (+42.80%)
Apr 13, 2026 8w ago	6-K BULLISH ★ 7/10	$9.46 $10.00	▲ +5.71%	▲ +4.93%	$14.28 (+50.95%)
Mar 30, 2026 10w ago	6-K MIXED ★ 6/10	$7.31 $7.44	▲ +1.78%	▼ −1.11%	$14.28 (+95.35%)
Mar 30, 2026 10w ago	EFFECT NEUTRAL ★ 4/10	$7.31 $7.44	▲ +1.78%	▼ −1.11%	$14.28 (+95.35%)

US Market Status

Market Closed — Opens Mon (48h 26m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access